(973) 286-6700 [email protected]
Total Page:16
File Type:pdf, Size:1020Kb
Case 2:17-cv-03159-ES-JAD Document 1 Filed 05/04/17 Page 1 of 135 PageID: 1 Charles M. Lizza William C. Baton Saul Ewing LLP One Riverfront Plaza, Suite 1520 Newark, NJ 07102-5426 (973) 286-6700 [email protected] Attorneys for Plaintiff Celgene Corporation UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY CELGENE CORPORATION, Civil Action No. ________________ Plaintiff, COMPLAINT FOR v. PATENT INFRINGEMENT PAR PHARMACEUTICAL, INC., PAR (Filed Electronically) PHARMACEUTICAL COMPANIES, INC., TEVA PHARMACEUTICALS USA, INC., and TEVA PHARMACEUTICAL INDUSTRIES LIMITED, Defendants. Plaintiff Celgene Corporation (“Celgene”), by its undersigned attorneys, for its Complaint against defendants Par Pharmaceutical, Inc. (“Par Pharmaceutical”), Par Pharmaceutical Companies, Inc. (“Par Pharmaceutical Cos.”) (Par Pharmaceutical and Par Pharmaceutical Cos. together, “Par”), Teva Pharmaceuticals USA, Inc. (“Teva USA”), and Teva Pharmaceutical Industries Limited (“Teva Ltd.”) (Teva USA and Teva Ltd. together, “Teva”) (collectively, “Defendants”) alleges as follows: Nature of the Action 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C. §100, et seq., arising from the Defendants’ filing of their respective Case 2:17-cv-03159-ES-JAD Document 1 Filed 05/04/17 Page 2 of 135 PageID: 2 Abbreviated New Drug Applications (“ANDAs”), Nos. 210245 (“Par’s ANDA”) and 209956 (“Teva’s ANDA”), with the United States Food and Drug Administration (“FDA”) seeking ® approval to commercially market generic versions of Celgene’s POMALYST drug products prior to the expiration of United States Patent Nos. 8,198,262 (the “’262 patent”), 8,673,939 (the “’939 patent), 8,735,428 (the “’428 patent”), and 8,828,427 (the “’427 patent”), all owned by Celgene (collectively, “the patents-in-suit”). The Parties 2. Plaintiff Celgene is a biopharmaceutical company committed to improving the lives of patients worldwide. Celgene focuses on, and invests heavily in, the discovery and development of products for the treatment of severe and life-threatening conditions, including cancer. Celgene is a world leader in the treatment of many such diseases, including cancer. Celgene is a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 86 Morris Avenue, Summit, New Jersey 07901. 3. On information and belief, Defendant Par Pharmaceutical is a corporation organized and existing under the laws of Delaware, having a principal place of business at One Ram Ridge Road, Chestnut Ridge, NY 10977. 4. On information and belief, Defendant Par Pharmaceutical Cos. is a corporation organized and existing under the laws of Delaware, having a principal place of business at One Ram Ridge Road, Chestnut Ridge, NY 10977. 5. On information and belief, Par Pharmaceutical is a wholly owned subsidiary of Par Pharmaceutical Cos. 6. On information and belief, Defendant Teva Pharmaceuticals USA, Inc. is a corporation organized and existing under the laws of Delaware, having a principal place of business at 1090 Horsham Road, North Wales, PA 19454. - 2 - Case 2:17-cv-03159-ES-JAD Document 1 Filed 05/04/17 Page 3 of 135 PageID: 3 7. On information and belief, Defendant Teva Pharmaceutical Industries Limited is a company organized and existing under the laws of Israel, having a principal place of business at 5 Basel Street, Petach Tikva 49131 Israel. 8. On information and belief, Teva USA is a wholly owned subsidiary of Teva Ltd. The Patents-in-Suit 9. On June 12, 2012, the United States Patent and Trademark Office (“USPTO”) duly and lawfully issued the ’262 patent, entitled, “Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione,” to Celgene as assignee of the inventor Jerome B. Zeldis. A copy of the ’262 patent is attached hereto as Exhibit A. 10. On March 18, 2014, the USPTO duly and lawfully issued the ’939 patent, entitled, “Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))- isoindoline-1,3-dione,” to Celgene as assignee of the inventor Jerome B. Zeldis. A copy of the ’939 patent is attached hereto as Exhibit B. 11. On May 27, 2014, the USPTO duly and lawfully issued the ’428 patent, entitled, “Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))- isoindoline-1,3-dione,” to Celgene as assignee of the inventor Jerome B. Zeldis. A copy of the ’428 patent is attached hereto as Exhibit C. 12. On September 9, 2014, the USPTO duly and lawfully issued the ’427 patent, entitled, “Formulations of 4-amino-2-(2,6-dioxopiperidine-3-YL)isoindoline-1,3-dione,” to Celgene as assignee of the inventors Anthony Tutino and Michael T. Kelly. A copy of the ’427 patent is attached hereto as Exhibit D. - 3 - Case 2:17-cv-03159-ES-JAD Document 1 Filed 05/04/17 Page 4 of 135 PageID: 4 ® The POMALYST Drug Product 13. Celgene holds an approved New Drug Application (“NDA”) under Section 505(a) of the Federal Food Drug and Cosmetic Act (“FFDCA”), 21 U.S.C. § 355(a), for ® pomalidomide capsules (NDA No. 204026), which it sells under the trade name POMALYST . ® POMALYST is an FDA-approved medication used for the treatment of multiple myeloma. 14. The claims of the patents-in-suit cover, inter alia, methods of use and administration of pomalidomide, or pharmaceutical compositions containing pomalidomide. 15. Pursuant to 21 U.S.C. § 355(b)(1) and attendant FDA regulations, the patents-in-suit are listed in the FDA publication, “Approved Drug Products with Therapeutic ® Equivalence Evaluations” (the “Orange Book”), with respect to POMALYST . ® 16. The labeling for POMALYST instructs and encourages physicians, pharmacists, ® and other healthcare workers and patients to administer POMALYST according to one or more of the methods claimed in the patents-in-suit. Jurisdiction and Venue 17. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202. 18. Venue is proper in this Judicial District pursuant to 28 U.S.C. §§ 1391 and 1400(b). Personal Jurisdiction: Par 19. This Court has personal jurisdiction over Par Pharmaceutical by virtue of, inter alia, its systematic and continuous contacts with the State of New Jersey. On information and belief, Par Pharmaceutical is registered with the State of New Jersey’s Division of Revenue and Enterprise Services as a business operating in New Jersey under Business Id. No. 0100071541. On information and belief, Par Pharmaceutical is registered with the State of New Jersey’s - 4 - Case 2:17-cv-03159-ES-JAD Document 1 Filed 05/04/17 Page 5 of 135 PageID: 5 Department of Health as a manufacturer and wholesaler of drugs under Registration No. 5004032. On information and belief, Par Pharmaceutical purposefully has conducted and continues to conduct business in this Judicial District. By virtue of its physical presence in New Jersey, this Court has personal jurisdiction over Par Pharmaceutical. 20. On information and belief, Par Pharmaceutical is in the business of, among other things, manufacturing, marketing, importing, offering for sale, and selling pharmaceutical products, including generic drug products, throughout the United States, including in this Judicial District. On information and belief, this Judicial District will be a destination for the generic drug product described in Par’s ANDA. On information and belief, Par Pharmaceutical also prepares and/or aids in the preparation and submission of ANDAs to the FDA. 21. This Court has personal jurisdiction over Par Pharmaceutical Cos. because, inter alia, it: (1) has purposely availed itself of the privilege of doing business in New Jersey, including directly or indirectly through its subsidiary, agent, and/or alter ego, Par Pharmaceutical, a company registered with the State of New Jersey’s Department of Health as a drug manufacturer and wholesaler; and (2) maintains extensive and systematic contacts with the State of New Jersey, including the marketing, distribution, and/or sale of generic pharmaceutical drugs in New Jersey including through, directly or indirectly, Par Pharmaceutical. 22. This Court has personal jurisdiction over Par because, inter alia, it has committed an act of patent infringement under 35 U.S.C. § 271(e)(2), and has sent notice of that infringement to Celgene in the State of New Jersey. On information and belief, Par intends a future course of conduct that includes acts of patent infringement in New Jersey. These acts have led and will continue to lead to foreseeable harm and injury to Celgene in New Jersey and in this Judicial District. - 5 - Case 2:17-cv-03159-ES-JAD Document 1 Filed 05/04/17 Page 6 of 135 PageID: 6 23. Endo International PLC acquired Par Pharmaceutical Holdings, Inc. on September 25, 2015. Endo International’s 2015 Form 10-K states, “Immediately following the closing, Par Pharmaceutical Holdings, Inc. changed its name to Par Pharmaceutical Companies, Inc. (Par).” See Endo Form 10-K at 3. The Endo Form 10-K also states that “Par has operated in two business segments, (i) Par Pharmaceutical, which includes generic products … and (ii) Par Specialty Pharmaceuticals, which markets three branded products.” Id. 24. On information and belief, Par Pharmaceutical and Par Pharmaceutical Cos. work in concert with respect to the regulatory approval, manufacturing, marketing, sale, and distribution of generic pharmaceutical products throughout the United States, including in this Judicial District. 25. On information and belief, Par Pharmaceutical acts at the direction, and for the benefit, of Par Pharmaceutical Cos., and is controlled and/or dominated by Par Pharmaceutical Cos. 26. On information and belief, both Par Pharmaceutical and Par Pharmaceutical Cos. have previously been sued in this Judicial District and have not challenged personal jurisdiction. See, e.g., Alcon Labs.